KR20150048663A - 패혈증 치료를 위한 티모신 알파의 용도 - Google Patents

패혈증 치료를 위한 티모신 알파의 용도 Download PDF

Info

Publication number
KR20150048663A
KR20150048663A KR1020147027456A KR20147027456A KR20150048663A KR 20150048663 A KR20150048663 A KR 20150048663A KR 1020147027456 A KR1020147027456 A KR 1020147027456A KR 20147027456 A KR20147027456 A KR 20147027456A KR 20150048663 A KR20150048663 A KR 20150048663A
Authority
KR
South Korea
Prior art keywords
sepsis
days
day
thymosin peptide
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020147027456A
Other languages
English (en)
Korean (ko)
Inventor
신시아 투트힐
샹동 구안
지안펑 우
Original Assignee
사이클론 파아머슈티컬 인코오퍼레이티드
퍼스트 어필리에이티드 하스피틀, 쑨 얏-센 유니버시티
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 사이클론 파아머슈티컬 인코오퍼레이티드, 퍼스트 어필리에이티드 하스피틀, 쑨 얏-센 유니버시티 filed Critical 사이클론 파아머슈티컬 인코오퍼레이티드
Publication of KR20150048663A publication Critical patent/KR20150048663A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2292—Thymosin; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
KR1020147027456A 2012-03-30 2013-03-28 패혈증 치료를 위한 티모신 알파의 용도 Ceased KR20150048663A (ko)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201261618563P 2012-03-30 2012-03-30
US61/618,563 2012-03-30
US201261643824P 2012-05-07 2012-05-07
US61/643,824 2012-05-07
US13/835,107 US20130296223A1 (en) 2012-03-30 2013-03-15 Use of thymosin alpha for the treatment of sepsis
US13/835,107 2013-03-15
PCT/US2013/034394 WO2013149030A2 (en) 2012-03-30 2013-03-28 Use of thymosin alpha for the treatment of sepsis

Publications (1)

Publication Number Publication Date
KR20150048663A true KR20150048663A (ko) 2015-05-07

Family

ID=49261395

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020147027456A Ceased KR20150048663A (ko) 2012-03-30 2013-03-28 패혈증 치료를 위한 티모신 알파의 용도

Country Status (8)

Country Link
US (5) US20130296223A1 (enExample)
EP (2) EP2841088B1 (enExample)
JP (6) JP2015514093A (enExample)
KR (1) KR20150048663A (enExample)
CN (2) CN107519483A (enExample)
CA (1) CA2866435A1 (enExample)
HK (1) HK1246694A1 (enExample)
WO (1) WO2013149030A2 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017524943A (ja) * 2014-08-12 2017-08-31 アルサニス・バイオサイエンスズ・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング Ｓ．アウレウス疾患の予測
WO2019028448A1 (en) * 2017-08-04 2019-02-07 The Johns Hopkins University APPLICATION FOR EARLY PREDICTION OF SEPTIC SHOCK WAITING
US11504071B2 (en) * 2018-04-10 2022-11-22 Hill-Rom Services, Inc. Patient risk assessment based on data from multiple sources in a healthcare facility
SMT202400412T1 (it) * 2018-04-20 2024-11-15 Combioxin Sa Trattamento dell'ipotensione con sepsi o shock settico
WO2023285349A1 (en) 2021-07-12 2023-01-19 2N Pharma Aps Carnitine-palmitoyl-transferase-1 (cpt-1) inhibitors for use in a method of preventing or treating sepsis in a mammalian subject

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4079127A (en) 1976-10-28 1978-03-14 Board Of Regents Of The University Of Texas Thymosin alpha 1
WO1995009647A1 (en) * 1993-10-07 1995-04-13 The George Washington University Medical Center METHOD OF TREATING SEPTIC SHOCK USING THYMOSIN-α¿1?
TW252045B (enExample) * 1993-10-07 1995-07-21 Allan L Goldstein
US5972933A (en) * 1998-01-08 1999-10-26 Ed. Geistlich Sohne Ag Fur Chemische Industrie Method of treating microbial infections
UA80957C2 (en) 2001-11-01 2007-11-26 Sciclone Pharmaceuticals Inc Method of administering a thymosin alpha 1 peptide
US7897567B2 (en) * 2002-11-25 2011-03-01 Sciclone Pharmaceuticals, Inc. Methods of protecting against radiation damage using alpha thymosin
US9205050B2 (en) * 2005-09-29 2015-12-08 Bayer Intellectual Property Gmbh Antibiotic formulations, unit doses, kits and methods
CN101020048A (zh) * 2007-02-12 2007-08-22 广东天普生化医药股份有限公司 一种用于治疗脓毒症的药物组合物
MX2009009657A (es) * 2007-03-21 2009-09-22 Bausch & Lomb Fluoroquinolonas para el tratamiento, reduccion, mejora, o prevencion de las infecciones provocadas por las bacterias resistentes a los farmacos antibacterianos.
JP2011506436A (ja) * 2007-12-12 2011-03-03 サイクローン・ファーマシューティカルズ・インコーポレイテッド 細胞傷害性ｔリンパ球抗原４（ｃｔｌａ４）に対する抗体と組み合わせられたアルファチモシンペプチドによる黒色腫の処置の方法
CN101514228A (zh) * 2008-02-21 2009-08-26 张卓兵 N-端修饰的人胸腺肽α1复合物及其制备方法
ES2537785T3 (es) * 2009-05-08 2015-06-12 Sciclone Pharmaceuticals, Inc. Péptidos de alfa timosina como potenciadores de vacunas
EP2416800A1 (en) * 2010-02-25 2012-02-15 Agennix AG Oral lactoferrin in the treatment of severe sepsis
CN103458681A (zh) * 2011-02-09 2013-12-18 赛生制药有限公司 用于预防感染、降低感染的严重性、及治疗感染的胸腺素α肽

Also Published As

Publication number Publication date
CA2866435A1 (en) 2013-10-03
JP2025107346A (ja) 2025-07-17
JP2017214377A (ja) 2017-12-07
JP2019156854A (ja) 2019-09-19
WO2013149030A2 (en) 2013-10-03
US20240091314A1 (en) 2024-03-21
JP2021100983A (ja) 2021-07-08
JP2015514093A (ja) 2015-05-18
HK1246694A1 (zh) 2018-09-14
JP2022176345A (ja) 2022-11-25
EP2841088A4 (en) 2015-10-14
CN105338996A (zh) 2016-02-17
CN107519483A (zh) 2017-12-29
US20150024994A1 (en) 2015-01-22
US20180236036A1 (en) 2018-08-23
HK1207314A1 (en) 2016-01-29
EP3741386A1 (en) 2020-11-25
EP2841088B1 (en) 2020-06-17
US20210106656A1 (en) 2021-04-15
EP2841088A2 (en) 2015-03-04
US20130296223A1 (en) 2013-11-07

Similar Documents

Publication Publication Date Title
US20240091314A1 (en) Use of thymosin alpha for the treatment of sepsis
JP2002544286A (ja) 免疫反応が十分に発揮し得ない個体の治療におけるマンナン結合性レクチン（ｍｂｌ）の新規適用
Tavares et al. Immunoneutralization of the aminoprocalcitonin peptide of procalcitonin protects rats from lethal endotoxaemia: neuroendocrine and systemic studies
Hua et al. Substance P promotes epidural fibrosis via induction of type 2 macrophages
Matsubara et al. Severe developmental delay and epilepsy in a Japanese patient with severe congenital neutropenia due to HAX1 deficiency
US20170198011A1 (en) Composition for treating sepsis or septic shock comprising the peptide originated from the smad6
US20230285390A1 (en) Methods of treating pulmonary injury with cgrp inhibitors
Marzoog Pulmonary fibrosis; risk factors and molecular triggers, insight for neo therapeutic approach
EP3355909B1 (en) Methods for treating diseases mediated by erbb4-positive pro-inflammatory macrophages
CN103648515B (zh) 作为辐射缓和剂和辐射防护剂的bpi和其同源物
HK40035899A (en) Use of thymosin alpha for the treatment of sepsis
HK1207314B (en) Use of thymosin alpha for the treatment of sepsis
CN104800831B (zh) 寡肽联合或与哌替啶的组合在制备用于镇痛的药物中的用途
CN104800829A (zh) 寡肽联合或与吗啡的组合在制备用于镇痛的药物中的用途
HK1259364B (en) Methods for treating diseases mediated by erbb4-positive pro-inflammatory macrophages
CN104800827A (zh) 寡肽在制备用于提高delta阿片受体表达的药物中的用途
CN104800835A (zh) 寡肽联合或与脑啡肽的组合在制备用于镇痛的药物中的用途

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20140929

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20180328

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20190220

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20191120

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20190220

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

X091 Application refused [patent]
AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20191120

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20190820

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20180328

Comment text: Amendment to Specification, etc.

PX0601 Decision of rejection after re-examination

Comment text: Decision to Refuse Application

Patent event code: PX06014S01D

Patent event date: 20200224

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20200219

Comment text: Decision to Refuse Application

Patent event code: PX06011S01I

Patent event date: 20191120

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20190820

Comment text: Notification of reason for refusal

Patent event code: PX06013S01I

Patent event date: 20190220

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20180328

PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20200525